{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:36:24Z","timestamp":1785576984871,"version":"3.56.0"},"reference-count":120,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:00:00Z","timestamp":1340841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Tuberculosis is the second leading cause of infectious deaths globally. Many effective conventional antimycobacterial drugs have been available, however, emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) has overshadowed the effectiveness of the current first and second line drugs. Further, currently available agents are complicated by serious side effects, drug interactions and long-term administration. This has prompted urgent research efforts in the discovery and development of new anti-tuberculosis agent(s). Several families of compounds are currently being explored for the treatment of tuberculosis. This review article presents an account of the existing chemotherapeutics and highlights the therapeutic potential of emerging molecules that are at different stages of development for the management of tuberculosis disease.<\/jats:p>","DOI":"10.3390\/ph5070690","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T11:17:49Z","timestamp":1340882269000},"page":"690-718","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Chemotherapeutic Interventions Against Tuberculosis"],"prefix":"10.3390","volume":"5","author":[{"given":"Neeraj","family":"Shakya","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, 728-Heritage Medical Research Center, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2S2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mangalayatan University, Beswan, Aligarh 202 145, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babita","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Surgery, 728-Heritage Medical Research Center, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2S2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, 728-Heritage Medical Research Center, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2S2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2012,6,28]]},"reference":[{"key":"ref_1","unstructured":"WHO Global Task Force outlines measures to combat XDR-TB worldwide (17 October 2006). Available online:http:\/\/www.who.int\/mediacentre\/news\/notes\/2006\/np29\/en\/index.html\/."},{"key":"ref_2","unstructured":"Rowland, K. Totally drug-resistant TB emerges in India, Nature News. Available online:http:\/\/www.nature.com\/news\/totally-drug-resistant-tb-emerges-in-india-1.9797\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm0211-159","article-title":"Tuberculosis vaccines\u2014A new kid on the block","volume":"17","author":"Kaufmann","year":"2011","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jac\/29.6.719","article-title":"Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges","volume":"29","author":"Nau","year":"1992","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.2174\/138161206778743646","article-title":"Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities","volume":"12","author":"Tomioka","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tube.2010.02.001","article-title":"Rifamycins-obstacles and opportunities","volume":"90","author":"Aristoff","year":"2010","journal-title":"Tuberculosis"},{"key":"ref_7","unstructured":"The American Thoracic Society [ATS]. Available online:http:\/\/www.thoracic.org\/assemblies\/mtpi\/resources\/istc-report.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1128\/AAC.37.10.2054","article-title":"Direct, automated detection of rifampin-resistant mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis","volume":"37","author":"Telenti","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","unstructured":"International Programme on Chemical Safety [INCHEM]. Available online:http:\/\/www.inchem.org\/documents\/pims\/pharm\/rifam.htm#SectionTitle:2.1%20Main%20\u2014risks%20and%20target%20organs\/ and reference therein\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1086\/430066","article-title":"Treatment of multidrug-resistant tuberculosis during pregnancy: Long-term follow-up of 6 children with intrauterine exposure to second-line agents","volume":"40","author":"Drobac","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1055\/s-2008-1038264","article-title":"Case report-tuberculosis in a health care worker during pregnancy","volume":"62","author":"Peters","year":"2008","journal-title":"Pneumologie"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/MAJ.0b013e31814a586a","article-title":"Update on rifampin and rifabutin drug interactions","volume":"335","author":"Baciewicz","year":"2008","journal-title":"Am. J. Med. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/bmj.1.4854.130","article-title":"Bactericidal activity of streptomycin and isoniazid against tubercle bacilli","volume":"130","author":"Singh","year":"1954","journal-title":"Br. Med. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1365-2958.2006.05467.x","article-title":"Mechanisms of action of isoniazid","volume":"62","author":"Timmins","year":"2006","journal-title":"Mol. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1074\/jbc.M808106200","article-title":"An oxyferrous heme\/protein-based radical intermediate is catalytically competent in the catalase reaction of Mycobacterium tuberculosis catalase-peroxidase (KatG)","volume":"284","author":"Suarez","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/598192","article-title":"Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: Implications for international pediatric dosing guidelines","volume":"48","author":"McIlleron","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF01086149","article-title":"Pharmacokinetics of Isoniazid Metabolism in Man","volume":"4","author":"Ellard","year":"1976","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"ref_18","unstructured":"International Programme on Chemical Safety [INCHEM]. Available online:http:\/\/www.inchem.org\/documents\/pims\/pharm\/pim288.htm#SectionTitle:2.1%20%20Main%20risks%20and%20target%20organs\/."},{"key":"ref_19","unstructured":"Yu, V.L., Merigan, T.C., and Barriere, S.L. (1999). Antimicrobial Therapy and Vaccines, Williams and Wilkins."},{"key":"ref_20","unstructured":"(1981). Controlled trial of four thrice weekly regimens and a daily regimen given for 6 months for pulmonary tuberculosis. Lancet, 1, 171\u2013174."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00006454-198807000-00003","article-title":"Cerebrospinal fluid pyrazinamide concentrations in children with tuberculous meningitis","volume":"7","author":"Donald","year":"1988","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_22","first-page":"6","article-title":"The Curious characteristics of pyrazinamide: A review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/AAC.01369-06","article-title":"Pyrazinoic acid and its n\u2019Propyl Ester Inhibit Fatty Acid Synthase I in Replicating Tubercle Bacilli","volume":"51","author":"Zimhony","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.5588\/ijtld.12.0083","article-title":"The chemotherapy of tuberculosis: Past, present and future","volume":"16","author":"Mitchison","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nm0696-662","article-title":"Mutations In pnca, a gene encoding pyrazinamidase\/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus","volume":"2","author":"Scorpio","year":"1996","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/AAC.41.3.540","article-title":"Characterization of pncA Mutations in pyrazinamide-resistant Mycobacterium tuberculosis","volume":"41","author":"Scorpio","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1128\/AAC.00110-08","article-title":"Pyrazinamide resistance and PNCA gene mutations in Mycobacterium tuberculosis","volume":"52","author":"Jureen","year":"2008","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF00558302","article-title":"Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects","volume":"36","author":"Lacroix","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/14740338.5.2.231","article-title":"Adverse reactions to first-line antituberculosis drugs","volume":"5","author":"Forget","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm0597-567","article-title":"The Emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol","volume":"3","author":"Telenti","year":"1997","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1073\/pnas.93.21.11919","article-title":"The Embab genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol","volume":"93","author":"Belanger","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1128\/AAC.43.3.568","article-title":"Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids","volume":"43","author":"Peloquin","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","unstructured":"Ethambutol (Ethambutol Hydrochloride)-Indications and Dosage. Available online:http:\/\/www.druglib.com\/druginfo\/ethambutol\/indications_doses\/."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.47102\/annals-acadmedsg.V35N4p274","article-title":"Ethambutol-associated optic neuropathy","volume":"35","author":"Lim","year":"2006","journal-title":"Ann. Acad. Med. Singapore"},{"key":"ref_35","unstructured":"Source partly from: North Dakota Department of Health. Available online:http:\/\/www.ndhealth.gov\/disease\/tb\/Documents\/Second line TB drugs.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1128\/AAC.32.8.1131","article-title":"MIC as a quantitative measurement of susceptibility of M. Avium to seven antituberculosis drugs","volume":"32","author":"Heifets","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/AAC.33.8.1298","article-title":"Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against M. Avium and M. tuberculosis","volume":"33","author":"Heifets","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.molcel.2006.05.044","article-title":"Douthwaite S. Capreomycin binds across the ribosomal subunit interface using Tlya-encoded 2'-O-methylations in 16S and 23S rRNAs","volume":"23","author":"Johansen","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_39","unstructured":"Available online:http:\/\/wonder.cdc.gov\/wonder\/prevguid\/p0000413\/p0000413.asp#head006001000000000\/."},{"key":"ref_40","first-page":"752","article-title":"Activities of clofazimine against Mycobacterium tuberculosis in vitro and in vivo","volume":"31","author":"Lu","year":"2008","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/AAC.40.7.1610","article-title":"In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis","volume":"40","author":"Rastogi","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/jac\/44.5.647","article-title":"Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin","volume":"44","author":"Vacher","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/jac\/19.5.617","article-title":"Activity of ciprofloxacin against Mycobacteria in vitro: Comparison of BACTEC and macrobroth dilution methods","volume":"19","author":"Trimble","year":"1987","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_44","unstructured":"Murray, P.R., Baron, E.J., Pfaller, M.A., Tenover, F.C., and Yolken, R.H. (1999). Manual of Clinical Microbiology, ASM Press. [III]."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1021\/jm040847w","article-title":"Discovery of bicyclic thymidine analogues as selective and high-affinity inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase","volume":"47","author":"Vanheusden","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/31159","article-title":"Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence","volume":"393","author":"Cole","year":"1998","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6663","DOI":"10.1016\/j.bmc.2005.07.046","article-title":"Synthesis and in vitro anti-mycobacterial activity of 5-substituted pyrimidine nucleosides","volume":"13","author":"Johar","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/JCM.36.2.362-366.1998","article-title":"Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis Isolates by using the microplate alamar blue assay","volume":"36","author":"Franzblau","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/S0960-894X(02)00551-6","article-title":"Synthesis and evaluation of thymidine-5O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase","volume":"12","author":"Vanheusden","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1016\/S0960-894X(03)00643-7","article-title":"Thymidine and thymidine-5'O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase","volume":"13","author":"Vanheusden","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cbic.200300608","article-title":"Comparative study of purine and pyrimidine nucleoside analogues acting on the thymidylate kinases of Mycobacterium tuberculosis and of humans","volume":"4","author":"Pochet","year":"2003","journal-title":"ChemBioChem"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1021\/jm058167w","article-title":"Design and studies of novel 5-substituted alkynylpyrimidine nucleosides as potent inhibitors of mycobacteria","volume":"48","author":"Rai","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/jm0703901","article-title":"Growth inhibition of Mycobacterium bovis, Mycobacterium tuberculosis and Mycobacterium avium in vitro: Effect of 1-b-D-2'-b-D-arabinofuranosyl and 1-(2-deoxy-2-fluoro-b-D-2'-ribofuranosyl) pyrimidine nucleoside","volume":"50","author":"Johar","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1021\/jm070391t","article-title":"Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides","volume":"50","author":"Rai","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.bmc.2006.12.032","article-title":"Studies on acyclic pyrimidines as inhibitors of mycobacteria","volume":"15","author":"Srivastav","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1021\/jm100165w","article-title":"3-Bromo analogues of pyrimidine nucleosides as a new class of potent inhibitors of Mycobacterium tuberculosis","volume":"53","author":"Shakya","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1128\/AAC.45.8.2210-2214.2001","article-title":"Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment","volume":"45","author":"Bermudez","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6180","DOI":"10.1021\/jm100568q","article-title":"Inhibition of mycobacterial replication by pyrimidines possessing various c-5 functionalities and related 20-deoxynucleoside analogues using in vitro and in vivo models","volume":"53","author":"Srivastav","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1021\/jm2004688","article-title":"Synthesis and evaluation of 5-substituted 2'-deoxyuridine monophosphate analogues as inhibitors of flavin-dependent thymidylate synthase in mycobacterium tuberculosis","volume":"54","author":"Kogler","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1021\/jm051060o","article-title":"Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis","volume":"49","author":"Somu","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.1021\/jm8008037","article-title":"Inhibition of siderophore biosynthesis by 2-triazole substituted analogues of 5'-O-[N-(Salicyl)sulfamoyl]adenosine: Antibacterial nucleosides effective against Mycobacterium tuberculosis","volume":"51","author":"Gupte","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.bcp.2006.03.006","article-title":"Structure-activity relationship for nucleoside analogs as inhibitors or substrates of adenosine kinase from Mycobacterium tuberculosis I. Modifications to the adenine moiety","volume":"71","author":"Long","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1016\/j.bmc.2005.05.021","article-title":"Synthesis and antitubercular activities of Bis-glycosylated diamino alcohols","volume":"13","author":"Tripathi","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.bmcl.2007.02.024","article-title":"Synthesis of new sugar derivatives from stachys sieboldi miq and antibacterial evaluation against Mycobacterium tuberculosis, Mycobacterium avium, and Staphylococcus aureus","volume":"17","author":"Chiba","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.bmcl.2010.12.084","article-title":"Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivatives","volume":"21","author":"Horita","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.bmcl.2006.02.065","article-title":"Gatifloxacin derivatives: Synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase","volume":"16","author":"Sriram","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.bmcl.2007.11.110","article-title":"Novel ofloxacin derivatives: Synthesis, antimycobacterial and toxicological evaluation","volume":"18","author":"Dinakaran","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.bmc.2007.11.016","article-title":"Antimycobacterial activities of novel 2-(sub)-3-fluoro\/nitro-5, 12-dihydro-5-oxobenzothiazolo[3,2-A]quinoline-6-carboxylic acid","volume":"16","author":"Dinakaran","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ejmech.2008.02.031","article-title":"Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids","volume":"44","author":"Senthilkumar","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1021\/jm049952w","article-title":"Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents","volume":"48","author":"Jaso","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bmc.2008.10.086","article-title":"Selective activity against Mycobacterium tuberculosis of new quinoxaline 1,4-di-N-oxides","volume":"17","author":"Vicente","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/j.bmc.2010.02.024","article-title":"New 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents","volume":"18","author":"Ancizu","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1016\/j.bmcl.2007.06.064","article-title":"[1,2,3]Triazolo[4,5-h]quinolones. A new class of potent antitubercular agents against multidrug resistantnt Mycobacterium tuberculosis strains","volume":"17","author":"Carta","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ejmech.2011.01.053","article-title":"Synthesis and antimycobacterial activity of prodrugs of indeno[2,1-c]quinoline derivatives","volume":"46","author":"Upadhayaya","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1021\/jm900003c","article-title":"Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis","volume":"52","author":"Lilienkampf","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7274","DOI":"10.1016\/j.bmc.2010.08.016","article-title":"Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring","volume":"18","author":"Khoje","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1016\/j.bmcl.2010.08.046","article-title":"Novel dihydropyrimidines as a potential new class of antitubercular agents","volume":"20","author":"Trivedi","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.bmc.2007.04.003","article-title":"Synthesis of new S-derivatives of clubbed triazolyl thiazole as anti-Mycobacterium tuberculosis agents","volume":"15","author":"Shiradkar","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1021\/jm701372r","article-title":"5-tert-Butyl-N-pyrazol-4-yl-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide derivatives as novel potent inhibitors of Mycobacterium tuberculosis pantothenate synthetase: Initiating a quest for new antitubercular drugs","volume":"51","author":"Velaparthi","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ejmech.2004.06.014","article-title":"Synthesis and anti-tuberculosis activity of N-Aryl-C-nitroazoles","volume":"39","author":"Walczak","year":"2004","journal-title":"Eur. J. Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.1021\/jm901112f","article-title":"Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles","volume":"52","author":"Huang","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1021\/jm901207n","article-title":"Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"53","author":"Palmer","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1016\/j.ejmech.2009.05.009","article-title":"Preparation and antitubercular activities in vitro and in vivo of novel schiff bases of isoniazid","volume":"44","author":"Hearn","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ejmech.2007.08.003","article-title":"Synthesis and anti-mycobacterial activity of (E)-N'-(monosubstituted-benzylidene) isonicotinohydrazide derivatives","volume":"43","author":"Peralta","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1021\/ja109665t","article-title":"Design, synthesis, and study of a mycobactin-artemisinin conjugat that has selective and potent activity against tuberculosis and malaria","volume":"133","author":"Miller","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1128\/AAC.49.4.1447-1454.2005","article-title":"In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis","volume":"49","author":"Falzari","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1021\/jm050825p","article-title":"Structure-activity relationships at the 5-position of thiolactomycin: An intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.","volume":"49","author":"Kim","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1128\/AAC.40.12.2813","article-title":"Antimycobacterial action of thiolactomycin: An inhibitor of fatty acid and mycolic acid synthesis","volume":"40","author":"Slayden","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1021\/jm049389h","article-title":"Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase","volume":"48","author":"McFadden","year":"2005","journal-title":"J. Med.Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"411","DOI":"10.7164\/antibiotics.35.411","article-title":"Thiolactomycin, a new antibiotic. IV. Biological properties and chemotherapeutic activity in mice","volume":"35","author":"Miyakawa","year":"1982","journal-title":"J. Antibiot."},{"key":"ref_91","unstructured":"Available online:http:\/\/www.newtbdrugs.org\/."},{"key":"ref_92","unstructured":"TB Alliance, and Tuberculosis Trial Consortium [TBTC]) Available online:http:\/\/www.cdc.gov\/tb\/topic\/research\/tbtc\/introduction.htm\/."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1016\/j.bmc.2008.03.020","article-title":"Structure-activity relationship of truncated analogs of caprazamycins as potential anti-tuberculosis agents","volume":"16","author":"Hirano","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1016\/j.bmcl.2011.07.015","article-title":"Identification of SQ609 as a lead compound from a library of dipiperidines","volume":"21","author":"Bogatcheva","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/(SICI)1098-1128(199811)18:6<363::AID-MED1>3.0.CO;2-I","article-title":"Tuberculosis: A search for novel therapy starting with natural products","volume":"18","author":"Mitscher","year":"1998","journal-title":"Med. Res. Rev."},{"key":"ref_96","unstructured":"Global Alliance for TB Drug Development. \u201cBackground\u201d. Available online:http:\/\/www.tballiance.org\/new\/portfolio\/html-portfolio-item.php?id=29\/."},{"key":"ref_97","unstructured":"Balasubramanian, V., Gaonkar, S., Solapure, S., Sambandamurthy, V., Shandil, R., Mahesh, K.N., Sharma, S., Kaur, P., Deepthi, R., and Subbulakshmi, V. (Scheduled Presentation on Monday, 19 September 2011) AZD5847, an Oxazolidinone for the Treatment of Tuberculosis: Pre-clinical Studies. [Presentation no. F1-1364]. American Society for Microbiology, 1752 N Street NW Washington, DC. USA. Available online:http:\/\/www.abstractsonline.com\/plan\/ViewAbstract.aspx?mID=2789&sKey=5f3fa01a-9c86-4ebd-8cab-50756d6faa6f&cKey=c393491b-4fdf-42a8-8857-3756dce2a517&mKey={0C918954-D607-46A7-8073-44F4B537A439}\/."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1128\/AAC.01297-10","article-title":"Susceptibility of Clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480","volume":"55","author":"Alffenaar","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_99","unstructured":"Sinha, R.K., Arora, S.K., Sinha, N., and Modak, V.M. (2004). Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC), American Society for Microbiology."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1021\/cc020071p","article-title":"Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates","volume":"5","author":"Lee","year":"2003","journal-title":"J. Comb. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.bjp.0705984","article-title":"Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug","volume":"144","author":"Jia","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1164\/rccm.200507-1047OC","article-title":"Rifapentine, moxifloxacin, or dna vaccine improves treatment of latent tuberculosis in a mouse model","volume":"172","author":"Nuermberger","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1128\/AAC.49.6.2294-2301.2005","article-title":"Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models","volume":"49","author":"Lenaerts","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1128\/AAC.49.6.2289-2293.2005","article-title":"Bactericidal activity of the nitroimidazopyran PA-824 in the murine model of tuberculosis","volume":"49","author":"Tyagi","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","unstructured":"Matsumoto, M., Hshizume, H., Tomishige, T., and Kawasaki, M. (2005). Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC), American Society for Microbiology."},{"key":"ref_107","unstructured":"Kawasaki, M., Yamamoto, K., and Matusmoto, M. (2005). Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC), American Society for Microbiology."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1128\/AAC.00181-07","article-title":"In vitro antimycobacterial spectrum of a diarylquinoline atp-synthase inhibitor","volume":"51","author":"Huitric","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1128\/AAC.47.1.416-417.2003","article-title":"In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs","volume":"47","author":"Bouza","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1183\/09031936.00009509","article-title":"A retrospective TBNET assessment of linezolid, safety, tolerability and efficacy in multidrug resistant tuberculosis","volume":"34","author":"Migliori","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic effects of linezolid: Summary of clinical experience","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1128\/AAC.43.1.25","article-title":"Development of rifapentine susceptibility tests for Mycobacterium tuberculosis","volume":"43","author":"Heifets","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1128\/AAC.42.7.1853","article-title":"Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis","volume":"42","author":"Williams","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1164\/rccm.200305-682OC","article-title":"The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis","volume":"168","author":"Gosling","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/AAC.48.3.780-782.2004","article-title":"Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: A prospective, randomized study","volume":"48","author":"Pletz","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1179\/joc.2004.16.4.334","article-title":"Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains","volume":"16","author":"Tortoli","year":"2004","journal-title":"J. Chemother."},{"key":"ref_118","unstructured":"Bayer. Avelox\u00ae (moxifloxacin hydrochloride) Product Safety. Available online:http:\/\/www.avelox.com\/en\/physician\/product_information\/avelox_safety\/index.php."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1164\/rccm.200407-885OC","article-title":"Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis","volume":"170","author":"Nuermberger","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1128\/AAC.49.2.627-631.2005","article-title":"Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis","volume":"49","author":"Paramasivan","year":"2005","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/5\/7\/690\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:51:01Z","timestamp":1760219461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/5\/7\/690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,28]]},"references-count":120,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,7]]}},"alternative-id":["ph5070690"],"URL":"https:\/\/doi.org\/10.3390\/ph5070690","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,28]]}}}